US Stock MarketDetailed Quotes
ESPR Esperion Therapeutics
- 1.680
- +0.040+2.44%
Close Sep 27 16:00 ET
- 1.680
- 0.0000.00%
Post 20:02 ET
329.66MMarket Cap-1976P/E (TTM)
1.710High1.635Low2.73MVolume1.650Open1.640Pre Close4.57MTurnover1.40%Turnover RatioLossP/E (Static)196.22MShares3.40052wk High-0.96P/B327.30MFloat Cap0.70052wk Low--Dividend TTM194.82MShs Float120.960Historical High--Div YieldTTM4.57%Amplitude0.700Historical Low1.676Avg Price1Lot Size
Esperion Therapeutics Key Stats
Quarterly+Annual
YOY
| (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 70.89%-7.21M | 199.03%53.83M | 22.50%-135.49M | 12.75%-37.06M | 54.88%-19.33M | 51.02%-24.75M | -39.41%-54.36M | 33.73%-174.83M | 26.40%-42.47M | 38.07%-42.83M |
| Net income from continuing operations | -24.01%-61.93M | 198.87%61.02M | 10.45%-209.25M | -1.54%-56.34M | 25.16%-41.25M | 24.71%-49.94M | -8.79%-61.72M | 13.17%-233.66M | 14.79%-55.49M | 20.56%-55.12M |
| Depreciation and amortization | -80.39%10K | --0 | -67.20%164K | -93.48%6K | -75.24%26K | -66.00%51K | -47.06%81K | -18.30%500K | -39.87%92K | -31.37%105K |
| Other non cash items | -70.19%3.54M | -3.09%11.37M | 4.69%48.38M | 6.22%12.41M | 7.33%12.35M | 2.34%11.89M | 2.84%11.74M | 30.07%46.21M | 6.15%11.68M | 5.96%11.5M |
| Change In working capital | -149.20%-5M | -210.63%-21.8M | 505.43%13.68M | 278.72%3.96M | 317.34%6.58M | 3,275.42%10.16M | -548.21%-7.02M | 93.58%-3.37M | 60.37%-2.21M | 81.42%-3.03M |
| -Change in receivables | -31.11%-5.75M | -127.77%-6.12M | -36.78%-14.77M | -162.10%-5.87M | 49.96%-1.82M | -60.70%-4.38M | -23.10%-2.69M | -2.36%-10.8M | -83.01%-2.24M | -2,631.25%-3.65M |
| -Change in inventory | -79.85%-11.37M | -80.00%-7.47M | -3,669.76%-30.42M | -150.85%-14.19M | -1,739.94%-5.76M | -198.47%-6.32M | -229.44%-4.15M | 95.58%-807K | -1,240.28%-5.66M | 96.95%-313K |
| -Change in prepaid assets | -94.08%315K | -309.83%-6.59M | 336.36%6.19M | 794.98%4.64M | -16.35%-2.16M | 167.34%5.32M | -310.47%-1.61M | 1,333.33%1.42M | 151.96%518K | -107.27%-1.85M |
| -Change in payables and accrued expense | 69.71%20.49M | 22.88%-5.57M | 219.91%30.78M | 140.21%13.7M | 207.42%12.23M | 288.46%12.07M | -213.87%-7.22M | 135.40%9.62M | 240.64%5.7M | 194.58%3.98M |
| -Change in other working capital | -349.58%-8.68M | -54.36%3.95M | 879.18%21.9M | 1,155.58%5.68M | 442.46%4.09M | 240.22%3.48M | 511.90%8.65M | -160.37%-2.81M | -122.38%-538K | -11.17%-1.19M |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 70.89%-7.21M | 199.03%53.83M | 22.50%-135.49M | 12.75%-37.06M | 54.88%-19.33M | 51.02%-24.75M | -39.41%-54.36M | 33.73%-174.83M | 26.40%-42.47M | 38.07%-42.83M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -100.44%-77K | -100.29%-73K | 424.43%42.5M | 0 | 0 | 250.00%17.5M | 238.11%25M | 116.05%8.1M | 76.64%-11.79M | 33M |
| Net PPE purchase and sale | ---77K | ---73K | ---- | ---- | ---- | --0 | --0 | ---- | ---- | ---- |
| Net investment purchase and sale | --0 | --0 | 424.43%42.5M | --0 | --0 | 250.00%17.5M | 238.11%25M | 116.05%8.1M | 76.64%-11.79M | --33M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -100.44%-77K | -100.29%-73K | 424.43%42.5M | --0 | --0 | 250.00%17.5M | 238.11%25M | 116.05%8.1M | 76.64%-11.79M | --33M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | -3,811.12%-30.02M | 83.07%90.61M | 54.76%50.46M | 114.73%4.47M | -109.31%-4.31M | -95.53%809K | 3,546.52%49.49M | -87.84%32.61M | -114.23%-30.36M | 1,166.54%46.29M |
| Net common stock issuance | --0 | 72.39%90.67M | -37.40%56.88M | 138.44%52.43M | -207.82%-52.46M | -78.68%4.31M | --52.6M | -58.46%90.85M | -89.74%21.99M | 1,008.75%48.65M |
| Cash dividends paid | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 |
| Proceeds from stock option exercised by employees | 90,610.00%9.07M | --5.77M | --9.09M | ---43.36M | --52.44M | --10K | --0 | --0 | --0 | --0 |
| Net other financing activities | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -201.24%-50.22M | -40,100.00%-50M | --0 |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | -3,811.12%-30.02M | 83.07%90.61M | 54.76%50.46M | 114.73%4.47M | -109.31%-4.31M | -95.53%809K | 3,546.52%49.49M | -87.84%32.61M | -114.23%-30.36M | 1,166.54%46.29M |
| Net cash flow | ||||||||||
| Beginning cash position | 56.38%226.61M | -34.08%82.25M | -51.80%124.78M | -45.16%114.83M | -19.93%138.47M | -27.68%144.91M | -51.80%124.78M | -15.11%258.89M | 36.26%209.4M | -21.10%172.94M |
| Current changes in cash | -479.18%-37.31M | 616.93%144.36M | 68.29%-42.53M | 61.49%-32.59M | -164.83%-23.64M | 76.51%-6.44M | 134.40%20.14M | -191.12%-134.12M | -180.43%-84.62M | 155.65%36.46M |
| End cash Position | 36.71%189.3M | 56.38%226.61M | -34.08%82.25M | -34.08%82.25M | -45.16%114.83M | -19.93%138.47M | -27.68%144.91M | -51.80%124.78M | -51.80%124.78M | 36.26%209.4M |
| Free cash flow | 70.58%-7.28M | 198.89%53.76M | 22.50%-135.49M | 12.75%-37.06M | 54.88%-19.33M | 51.02%-24.75M | -39.41%-54.36M | 33.73%-174.83M | 26.40%-42.47M | 38.07%-42.83M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data